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Background: Although glucocorticoids are widely used in the treatment of patients with early rheumatoid arthritis,
the best dosage of glucocorticoids with regards to efficacy and safety is not known.
The aim of the study ‘Comparison of the efficacy and safety of two starting dosages of prednisolone in early active
rheumatoid arthritis’ (CORRA) is to compare two standard glucocorticoid starting dosages and the non-use of
glucocorticoids in the treatment of patients with early active rheumatoid arthritis on the background of the
established ‘anchor’ therapy with methotrexate.
Methods/design: CORRA is an investigator-initiated, randomized, multicenter, double-blind, placebo-controlled
trial with two treatment arms, starting with 60 mg or 10 mg prednisolone per day, tapered down to 5 mg prednisolone
within eight weeks, and one placebo arm, each arm comprising 150 patients. The duration of the intervention is
12 weeks. In parallel, all patients will be treated with methotrexate (usual dosage 15 mg/week). The primary efficacy
endpoint is the progression of radiographic joint damage after one year compared to baseline. Important secondary
endpoints are the percentage of patients in remission, patient global assessment of disease activity, and changes of
functional capacity. Safety monitoring is performed.
The statistical analysis is performed in three hierarchical steps. The first step is an analysis of covariance (α = 0.05) to
compare the group with the initial prednisolone dosage of 60 mg and the placebo group. In case of a statistically
significant result, the comparison of the group starting with 10 mg prednisolone with the placebo group will be
performed as a second step (α = 0.05). In case of superiority of the 10 mg prednisolone group versus the placebo
group, the third step will be a non-inferiority test for the 10 mg prednisolone group versus the 60 mg prednisolone
group (α = 0.025).
Discussion: The CORRA trial will yield information concerning the optimal glucocorticoid dosage schedule in the
treatment of patients with early rheumatoid arthritis.
Trial registration: This trial was registered on 19 November 2013 at ClinicalTrials.gov. Registration number: NCT02000336.
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Rheumatoid arthritis (RA) is a chronic disease character-
ized by inflammation of the peripheral joints leading to
disability, impaired functioning, and premature death. Ir-
reversible joint damage may occur very soon after disease
onset. The most important treatment strategy is the early
use of disease-modifying antirheumatic drugs (DMARD).
However, DMARD have a delayed onset of efficacy and
side effects may require cessation of treatment.
Glucocorticoids (GC) are fast-acting anti-inflammatory
drugs, now also considered as disease modifying because
of their ability to decelerate structural damage [1]. Espe-
cially during the first weeks of DMARD treatment, GC
are frequently used due to the rapid onset of their anti-
inflammatory efficacy. However, it is well known that
GC may have considerable side effects such as osteopor-
osis, diabetes mellitus, arterial hypertension, cardiovas-
cular events, glaucoma, tuberculosis, and weight gain
[2]. Hoes et al. [3] systematically analyzed the literature
on reported adverse events (AE) and found the risk of
AE to be 43 per 100 patient-years (95% confidence inter-
val (CI): 30 to 55).
There is good evidence of clinical, functional, and
structural efficacy for: 5 to 10 mg prednisolone (PRED)/
day over two years [4-7]; and initial dose of 60 mg
PRED, tapered to low or zero dose over six to eight
months [8,9] given in addition to DMARD [10]. How-
ever, in most rheumatology departments a dosage of 60
mg PRED is not used in the treatment of RA due to tox-
icity concerns. With the common implementation of
’treat-to-target’ strategies [11], including higher doses of
DMARD and a more rapid dose escalation, the percent-
age of patients undergoing concomitant GC treatment
over a long period may diminish. Thus, within a treat-
to-target setting, lower dosages of PRED taken over a
short period may render sufficient disease modification.
Usually, a low (<7.5 mg PRED equivalent a day) to
medium (>7.5 mg but <30 mg PRED equivalent) [12])
dose GC schedule is thought to provide sufficient benefit
[13]. Following the European League Against Rheuma-
tism (EULAR) recommendations [14], the dose is often
tapered as rapidly as is clinically feasible [15].
Therefore, most rheumatologists rather use 7.5 to 10
mg PRED in the initial treatment of RA, increasing the
dose in case of lack of efficacy, and tapering the dose over
the following weeks to bridge the interval until DMARD
become clinically efficacious. Unfortunately, there is insuf-
ficient data concerning this dosage schedule.
In order to shed further light on the best possible GC
treatment strategy in early RA regarding both efficacy
and safety, we have designed a study which may guide
future treatment decisions.
The main aims of this study are: to compare the use of
GC as a bridging therapy with placebo in a treat-to-target setting with DMARD, and to define the best out
of two standard GC dosage regimens. Both aims are with
regard to the progression of radiographic joint damage
after one year compared to baseline.
Methods/Design
Trial design
CORRA is a multicenter, randomized, placebo-controlled,
double-blind clinical trial conducted in 30 rheumatology
practices in North Rhine-Westphalia, Germany. Most
of these practices are members of the RheumaNetz
Westfalen-Lippe, a local cooperation of rheumatolo-
gists in the eastern part of North Rhine-Westphalia. In
total, 450 patients with early active RA will be random-
ized to receive one of two GC treatments (starting with
10 or 60 mg PRED, tapered down to 5 mg PRED within
eight weeks) or placebo, each arm comprising 150 pa-
tients. The duration of the intervention is 12 weeks. In
parallel, all patients start medication with methotrex-
ate (MTX), at a usual dosage of 15 mg/week. The pri-
mary efficacy endpoint is radiographic joint damage
after one year compared to baseline. Important sec-
ondary endpoints are the percentage of patients in re-
mission, patient global assessment of disease activity,
and changes of functional capacity. Safety monitoring
is performed.
The study is approved by the local ethic committees
Ethik-Kommission der Ärztekammer Westfalen-Lippe
und der Medizinischen Fakultät der Westfälischen
Wilhelms-Universität Münster (leading ethic commit-
tee: 2013-250-f-A), Ethik-Kommission der Ärztekammer
Nordrhein, Dusseldorf, and Ethikkommission bei der
Ärztekammer Niedersachsen, Hannover. It is registered at
the European Union Drug Regulating Authorities (EudraCT:
2012-004074-25), at ClinicalTrials.gov (NCT02000336), and
German Clinical Trials Register (DRKS-Nr: DRKS00004774).
The principles of good clinical practice will be an essential
component of the trial. It will be conducted in accordance
with the Declaration of Helsinki. All patients will be required
to give written informed consent before inclusion in the
study.
Participants
The 2010 RA classification criteria established by the
American College of Rheumatology/EULAR collabora-
tive initiative will be used in this trial to enable the early
diagnosis of RA [16]. In general, most patients enrolled
in this trial will be seen by a rheumatologist early in the
course of their disease. To meet the circumstances of
routine rheumatology care where patients are sometimes
seen with a delay of many months, patients with a dis-
ease duration of up to three years may be enrolled. In
general, patients will be MTX naïve (MTX pretreatment
of four weeks or less is allowed).
Table 1 Schedule of the prednisolone dosage (mg/day) of
the three study arms of the CORRA study
Day Placebo V10 V60
1 - 7 0 10 60
8 - 14 0 10 40
15 - 21 0 10 25
22 - 28 0 10 20
29 - 35 0 7,5 15
36 - 42 0 7,5 10
43 - 49 0 7,5 7,5
50 - 56 0 7,5 7,5
57 - 84 0 5 5
CORRA: Comparison of the efficacy and safety of two starting dosages of
prednisolone in early active rheumatoid arthritis, PRED: prednisolone, V10:
group starting with 10 mg PRED; V60: group starting with 60 mg PRED.
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activity must be moderate or high as measured by a Dis-
ease Activity Score 28 (DAS28) of >4. The DAS28 score
is a compound score comprising the number of tender
joints (out of 28), swollen joints (out of 28), the erythro-
cyte sedimentation rate (ESR, after 1 hour), and the pa-
tient’s assessment of disease activity. The range of the
score is 0 (no activity) to 10 (maximum disease activity)
[17]. In patients with a pain disorder such as fibromyal-
gia, the DAS28 score may be unduly elevated because of
the high number of tender joints. To ensure a sufficient
amount of inflammatory disease activity, the number of
swollen joints should be three or more for a patient to
be enrolled in the trial.
Key exclusion criteria will ensure that no patients with
very high risks for GC or MTX toxicity will participate
in the trial. The exclusion criteria are in accordance with
standard rheumatological decision-making and therefore
do not promote undue patient selection for this study.
To avoid an inappropriate risk of MTX toxicity, it is
mandatory to exclude patients with severe liver disease,
active hepatitis B or C viral infection, renal disease (cre-
atinine clearance <30 ml/minute), clinically relevant
hematological disease, relevant immunodeficiency in-
cluding HIV infection, clinically significant pulmonary fi-
brosis, complicated gastric or duodenal ulcer, a history
of malignant melanoma, pregnancy or planned preg-
nancy, or severe infections within the previous six weeks
before study participation.
Patients with uncontrolled diabetes mellitus, arterial
hypertension, or intraocular pressure should not receive
GC treatment and are therefore excluded as well. On
general grounds, non-compliant patients and patients
outside the range of 18 to 80 years will not be allowed
to participate.
Study medication, randomization, and follow-up
The intervention phase will last 84 days. The respective
PRED dosages of the treatment groups are listed in
Table 1.
In parallel, all patients will start MTX medication at a
usual dosage of 15 mg/week (modifications may be made
by the rheumatologist, for example due to minor renal
insufficiency or age).
Patients are seen every four weeks within the first
three months. In case of lack of efficacy, the MTX dose
will be increased to 20 mg/week and further up to 25
mg/week, after four or eight weeks, respectively. In the
further course of the study, a change of DMARD medi-
cation according to the EULAR recommendations [14]
is allowed in case of lack of efficacy and/or intolerable
side effects. These decisions are made by the treating
rheumatologist based on the treat–to-target paradigm
for RA [11].Study visits will take place at baseline and after 4, 8,
12, 24, and 52 weeks (Figure 1). Physical examination,
determination of DAS28, and safety measures including
lab examinations will be performed at every visit. Radio-
graphs of hands and feet will be done at baseline and
after one year. Functional assessments including the
EuroQol-5D [18], Patient Health Questionnaire-2 [19], and
physical functioning questionnaire Hannover (FFbH) [20]
are planned at baseline and after 12, 24, and 52 weeks. Dual-
Energy X-ray Absorptiometry (DXA) of the lumbar spine
and hip at baseline and after 24 weeks is planned in case of
at least one of the following: age >60 years for men, >50
years for women, current smoker, history of non-traumatic
fracture, parental history of hip fracture (Table 2).
Allocation concealment is ensured as the randomization
code will not be released until the end of the study.
Randomization will be performed using blocks with vari-
able block length according to centre. Quality assurance
and monitoring will be performed in 100% of data for the
inclusion and exclusion criteria, verification of treatment
compliance, primary endpoint, and AE. Other trial data will
undergo 100% source data verification for 20% of patients.
The treating rheumatologist will record all AE includ-
ing serious AE and, if necessary, make treatment adjust-
ments in accordance with the protocol. Serious AE are
defined as any adverse reaction resulting in any of the
following outcomes: a life-threatening condition or death,
a significant or permanent disability, a malignancy,
hospitalization or prolongation of hospitalization, a
congenital abnormality, or a birth defect.
Supervision of the trial will be performed by an in-
dependent data and safety monitoring board (DSMB).
In case of unexpected safety concerns the biostatisti-
cian of the DSMB will perform an interim analysis.
The committee will ensure adherence to protocol and
provide the funding organization with information and
advice.
Figure 1 Schedule of the CORRA study. CORRA: Comparison of the efficacy and safety of two starting dosages of prednisolone in early active
rheumatoid arthritis, DMARD: disease-modifying antirheumatic drug, MTX: methotrexate, PRED: prednisolone.
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One of the best evaluated and relevant outcome mea-
sures in the assessment of RA is the radiographic joint
damage as measured by the van der Heijde modification
of the Sharp score (SHS) [21]. This score reflects the struc-
tural damage caused by the inflammatory joint disease.
Radiographic joint damage, as assessed by the SHS or
other scoring systems, correlates with physical function
[22], employment status [23], and mortality [24]. The ef-
fects discussed in the literature are comparable to the ef-
fects assumed for this study. According to the ‘window
of opportunity’ concept, reduced radiological damage
early in the course of RA leads to a beneficial modifica-
tion of the long-term outcome. Therefore, the primary
outcome parameter will be the progression of radio-
graphic joint damage after one year compared to base-










Week 53 + +
CORRA: Comparison of the efficacy and safety of two starting dosages of prednisolo
EQ-5D: EuroQol-5D, DXA: Dual-Energy X-ray Absorptiometry.Secondary outcome parameter
Secondary endpoints will be: percentage of patients in
remission (as defined by DAS28 < 2.6) or in a state of
low disease activity (DAS28 ≥ 2.6 and DAS28 < 3.2) both
at week 13 and after one year, changes of FFbH at week
13 and after one year, decline in bone mineral density
(DXA lumbar spine and hip) at six months compared to
baseline, number and overall dose of GC injections, dir-
ect costs of treatment over one year, mean MTX dosage,
patient global assessment of disease activity, and per-
centage of patients who switch to biological treatment in
cases of inefficacy of conventional DMARD therapy.
Among all secondary endpoints, the DAS28 is the
most important since it is a well-established tool used to
assess disease activity in RA. In daily routine, it is fre-
quently used to guide therapeutic decision-making. Simi-











ne in early active rheumatoid arthritis, DAS28: Disease Activity Score 28,
Figure 2 Statistical analyses procedure of the CORRA study.
CORRA: Comparison of the efficacy and safety of two starting
dosages of prednisolone in early active rheumatoid arthritis, Pl:
placebo group, V10: group starting with 10 mg prednisolone daily,
V60: group starting with 60 mg prednisolone daily.
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portant prognostic markers in RA [20]. To assess the risk
of osteoporotic fractures, the measurement of bone
mineral density (done by DXA) is recommended by
the German ‘Dachverband Osteologie’. To estimate the
economic burden of RA, direct costs of treatment per
month over one year will be determined. To take into
account the total intra-articular dose of GC, the num-
ber and overall dose of GC injections is recorded. As a
lower GC dosage may lead to an increase in MTX dos-
age, the mean MTX dosage will be a secondary end-
point. To provide patients’ perspective of the effects of
the different treatment arms, patient global assessment
of disease activity is selected as a secondary endpoint.
As treatment with biologicals leads to reduced radio-
graphic joint damage that is comparable to the disease
modifying effect of GC, the percentage of patients who
switch to a biological treatment in cases of inefficacy
of conventional DMARD therapy will be assessed as a
secondary endpoint. Finally, a secondary analysis of
the primary outcome parameter will be performed,
adjusting for mean MTX dose, use of biologicals, and
mean GC dose during weeks 13 to 52.
Sample size
It is assumed that progression of radiographic joint dam-
age as measured by the SHS will be the same for both
dosage levels of PRED. For sample size calculation we
used data from the BeSt-study [9]. We thus assume an
effect of 3.7 and a standard deviation of 7.5. Accounting
for a 5% dropout rate, the effect will be 3.5. If 150 pa-
tients per group are included, a two sided t-test of super-
iority (α = 0.05) between one of the PRED groups and
the placebo group will give a power of >0.95. Accepting
a non-inferiority margin of 1.3 (one third of the known
placebo-verum difference) for the difference in progres-
sion between the PRED groups, the one sided non-
inferiority test in step three (at α = 0.025) will give a power
of >0.80, if 149 patients per PRED group are included. The
significance level of α = 0.025 was chosen according to the
European Medicines Agency guidelines [25]. Thus, the
final sample size has been set as 150 patients per group.
Blinding and statistical methods
All participating rheumatologists and radiologists will be
blinded against the interventions, thus assuring blinded
assessment of outcome variables.
The primary endpoint is the progression of radio-
graphic damage after one year compared to baseline
(measured by the SHS). Analysis will be performed in
three steps to compare the three groups (Pl: placebo
group; V10: group starting with 10 mg PRED; and V60:
group starting with 60 mg PRED). Primary analysis will
be conducted by analysis of covariance (ANCOVA) forV60 versus Pl, using baseline values as covariates and
12-month values as dependent variables. In case of a sta-
tistically significant result (α = 0.05), a comparison of
V10 versus Pl will be performed (α = 0.05). In case of su-
periority of V10 versus Pl, a non-inferiority test for V10
versus V60 will be performed (α = 0.025), as is shown in
Figure 2. A non-inferiority margin of 1.3 SHS points has
been selected.
Statistical analysis will be performed using an intention-
to-treat (ITT) approach. It is expected that 12-month results
will be missing for less than 5% of the patients (dropout
rate). In step one and two, missing radiographs after one
year are substituted by randomly selected radiographs of pa-
tients of the placebo group (both replacements by the same
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groups. In step three of the test procedure, missing values
will be excluded from the analysis. A sensitivity analysis will
be done for the effect of the replacement procedure (the
random replacement will be repeated several times).
Analysis of the secondary outcome parameters will be
performed by ITT using all available data. Continuous
characteristics of the groups will be compared using ana-
lysis of covariance adjusting for baseline data. Analysis
of categorical variables or proportions will be performed
using the chi-square test. An additional repeated mea-
sures analysis will be done for all quantitative endpoints
taken at several time points.
Discussion
The most frequently used dosage of 7.5 to 10 mg PRED
as a bridging treatment in early RA is a compromise be-
tween the good clinical short-term effect of GC and the
attempt to minimize the risk of AE. However, the first
months of RA are considered to be like a window of op-
portunity, with the best offer to change the course of the
disease. This window of opportunity should be used to
‘hit hard and early’ (provide aggressive treatment as soon
as possible) [14]. It may well be that higher dosages of
GC, as used in the COBRA study [8] and the BeSt-study
[9], have a higher impact on the outcome without a con-
siderable increase of AE. The answer to this question
would be highly relevant for the individual patient be-
cause of the increased possibility to induce a more favor-
able course of the disease. The immediate benefits for
society in general and for the economic expenditures in
particular are obvious.
The aim of our study is to test different treatment
strategies rather than to evaluate the dose-dependent ef-
fect of PRED on the Sharp score. This means to find an-
swers to two questions. Firstly, is it worthwhile to start
with a high-dose PRED treatment in active RA patients,
even if a treat-to-target approach is followed? Secondly,
is there any difference between initially high and low
PRED doses in the sense of benefit in radiographic pro-
gression? In the further course, there are many potential
confounders, such as imbalanced MTX use, imbalanced
GC use during weeks 13 to 52, and imbalanced use of
biologics. These imbalances may flaw the immediate ef-
fect of the PRED bridging on the Sharp score, but have
only a minor impact on the tested treatment strategies.
The possible results of our testing procedure may clarify
if high-dose PRED bridging is not superior to a placebo,
then the disease modifying effect of PRED no longer
plays a major role in a treat-to-target setting. If there is
a significant difference between high-dose PRED bridg-
ing and placebo, and low-dose PRED bridging is not
superior to a placebo, then high-dose bridging may be
strongly recommendable. If a low-dose bridging comparesto a significantly effective high-dose bridging, the EULAR
recommendation of merely regarding the symptomatic
effect of PRED is confirmed. If there are no differences
between all three groups even with sufficiently imbalanced
concomitant therapies, then only symptomatic effects of
PRED should guide treatment decisions.
Of course, these results must be judged by considering
other endpoints such as adverse events, clinical response
to treatment, and patient-related outcomes. Therefore
recommendations should take into account all these re-
sults. It is possible, depending on the results, that there
may remain sufficient uncertainty and, therefore, that a
confirmatory trial may be needed. Nonetheless, the primary
endpoint should not be blurred by these short-term results
because the focus lies on disease modification as measured
by the Sharp score.
Trial status
Recruitment started in February 2014 and is expected to
finish in 2016.
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